

Brett E Houk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12202093/publications.pdf>

Version: 2024-02-01

12
papers

3,414
citations

1040056

9
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

5402
citing authors

#	ARTICLE	IF	CITATIONS
1	KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	27.0	1,049
2	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. <i>Nature</i> , 2019, 575, 217-223.	27.8	1,375
3	Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 22-31.	1.6	4
4	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1888-1895.	7.0	99
5	Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 385-391.	0.4	35
6	Pharmacokinetics, Modeling, and Simulation in the Development of Sunitinib Malate: A Case Study. , 2011, , 261-284.		1
7	A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. <i>Clinical Cancer Research</i> , 2011, 17, 6831-6839.	7.0	123
8	Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 357-371.	2.3	428
9	Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3187-3192.	2.3	1
10	A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients. <i>Clinical Cancer Research</i> , 2009, 15, 2497-2506.	7.0	213
11	Pharmacokinetics of plasmid DNA in the rat. <i>Pharmaceutical Research</i> , 2001, 18, 67-74.	3.5	33
12	Kinetic modeling of plasmid DNA degradation in rat plasma. <i>AAPS PharmSci</i> , 1999, 1, 15-20.	1.3	53